Pillar Biosciences Stock
Pillar Biosciences specializes in sequencing technology platform and proprietary data analysis toolkit.
Sign up today and learn more about Pillar Biosciences Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Pillar Biosciences Stock
Pillar Biosciences is prized with its patent-pending targeted sequencing technology platform and a proprietary data analysis toolkit, which achieves high sensitivity and specificity with clinical samples. The platform provides a fast, simple and affordable targeted sequencing method for NGS-based oncology testing. The start-up has also released its beta version of Lung & Colon Cancer Somatic Mutation Panel and BRCA1 & BRCA2 Germline Mutation Panel to cancer centers and clinical testing companies in the US and China for validation studies. The company was founded in 2014 and is headquartered in Natick, Massachusetts.
Funding History
| August 2014 | $2.9M |
|---|---|
| May 2016 | $18.0M |
| November 2018 | $16.0M |
| February 2020 | $32.4M |
| May 2021 | $90.0M |
Management
Founder & CEO
Gang Song
Co-Founder and Chief Science Officer
Zhaohui Wang
Chief Operating Officer
Martin Zillmann
Chief Financial Officer
Vincent Ricci
Chief Executive Officer
Randy Pritchard
General Counsel
Christa Adkins
Interim CFO
Richard P. Shea
Chief Commercial Officer
Dan Harma
Press
technologynetworks - Mar, 2 2024
Beckman Coulter Life Sciences and Pillar Biosciences Announce NGS Application Development Pipelineglobenewswire - Jan, 19 2024
Global Genomic Cancer Panel & Profiling Market Report 2023 ...prnewswire - Jan, 19 2024
Illumina Reports Financial Results for Second Quarter of ...selectscience - Jan, 19 2024
Discover potential of bioprinting in healthcare applicationglobenewswire - Jan, 19 2024
Clinical Oncology Next Generation Sequencing Market ...EquityZen Recognized As:
